Back to Posters​
Poster

ADPD 2026 – DEVELOPMENT OF A NOVEL ULTRASENSITIVE MULTIPLEX PROTEOMIC PANEL FOR COMPREHENSIVE BRAIN HEALTH AND NEUROLOGICAL DISEASE PROFILING

Back to Publications​

Aims & Methods

Aims: Advancements in biomarker development for neurodegenerative diseases, especially Alzheimer’s Disease, have accelerated with ultra-sensitive technologies like NUcleic acid-Linked Immuno-Sandwich Assay1 (NULISA) that pushes the limit of proteomic detection in low volumes of biofluids. However, detailed characterization of brain health and disease progression has been limited by the availability of comprehensive high sensitivity multiplex panels that span the broad spectrum of neurological conditions.

Methods: To interrogate a broad range of neurological diseases, we have developed new assays for key biomarkers linked to Parkinson’s disease, Ataxia, Huntington’s disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and injury. These include post-translationally modified proteins such as pTau-205, pTau-212, and pParkin-S65, as well as disease driver mutant proteins such as mHTT and mATXN3 for the detection and monitoring of specific disease states and progression. This new panel was optimized and validated for plasma, serum and cerebrospinal fluid (CSF). Assay characteristics were assessed for precision/reproducibility, sample detectability, specificity, and dilution linearity.

View Poster
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.